Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind'

29th October 2025 Uncategorised 0

In a bid to ensure that the widest swath of people with generalized myasthenia gravis (gMG) can benefit from its blockbuster medicine, argenx is heading to the FDA with positive data in a subset of patients long overlooked in the treatment paradigm.

More: Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind'
Source: fierce